In collection, these data reveal the benefits of MEG3 in alleviating NAFLD and suggest these benefits are associated with downregulating EZH2, upregulating SIRT6, and suppressing lipogenesis and inflammation. This evidence concerns the gene MEG3 and metabolic dysfunction-associated steatotic liver disease.